INR 688.55
(0.19%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 296.76 Million INR | -17.69% |
2022 | 360.56 Million INR | 14.59% |
2021 | 314.66 Million INR | -21.21% |
2020 | 399.38 Million INR | 6.05% |
2019 | 376.59 Million INR | 20.28% |
2018 | 313.11 Million INR | -1.44% |
2017 | 317.68 Million INR | -2.85% |
2016 | 326.98 Million INR | -46.32% |
2015 | 609.17 Million INR | 3.61% |
2014 | 587.94 Million INR | 1.95% |
2013 | 576.68 Million INR | 5.56% |
2012 | 546.29 Million INR | -5.21% |
2011 | 576.3 Million INR | 31.56% |
2010 | 438.04 Million INR | 22.81% |
2009 | 356.69 Million INR | -16.29% |
2008 | 426.08 Million INR | -22.84% |
2007 | 552.2 Million INR | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | -1.87 Billion INR | -731.49% |
2024 Q2 | 610.95 Million INR | 132.6% |
2023 Q2 | 399.95 Million INR | 0.0% |
2023 Q3 | - INR | -100.0% |
2023 Q4 | 296.76 Million INR | 0.0% |
2023 Q1 | - INR | -100.0% |
2023 FY | 296.76 Million INR | -17.69% |
2022 FY | 360.56 Million INR | 14.59% |
2022 Q4 | 360.56 Million INR | 0.0% |
2022 Q3 | - INR | -100.0% |
2022 Q1 | - INR | -100.0% |
2022 Q2 | 274.18 Million INR | 0.0% |
2021 Q1 | - INR | -100.0% |
2021 FY | 314.66 Million INR | -21.21% |
2021 Q4 | 314.66 Million INR | 0.0% |
2021 Q3 | - INR | -100.0% |
2021 Q2 | 672.48 Million INR | 0.0% |
2020 FY | 399.38 Million INR | 6.05% |
2020 Q3 | - INR | -100.0% |
2020 Q2 | 456.8 Million INR | 0.0% |
2020 Q4 | 399.38 Million INR | 0.0% |
2019 Q2 | 366.09 Million INR | 0.0% |
2019 Q1 | - INR | -100.0% |
2019 Q3 | - INR | -100.0% |
2019 FY | 376.59 Million INR | 20.28% |
2019 Q4 | 376.59 Million INR | 0.0% |
2018 FY | 313.11 Million INR | -1.44% |
2018 Q4 | 313.11 Million INR | 0.0% |
2018 Q3 | - INR | -100.0% |
2018 Q2 | 274.1 Million INR | 0.0% |
2018 Q1 | - INR | -100.0% |
2017 FY | 317.68 Million INR | -2.85% |
2017 Q1 | - INR | -100.0% |
2017 Q2 | 278.32 Million INR | 0.0% |
2017 Q4 | 317.68 Million INR | 0.0% |
2016 Q3 | - INR | -100.0% |
2016 FY | 326.98 Million INR | -46.32% |
2016 Q4 | 326.98 Million INR | 0.0% |
2016 Q2 | 671.31 Million INR | 0.0% |
2016 Q1 | - INR | -100.0% |
2015 Q1 | - INR | -100.0% |
2015 Q2 | 592.9 Million INR | 0.0% |
2015 Q4 | 609.17 Million INR | 0.0% |
2015 Q3 | - INR | -100.0% |
2015 FY | 609.17 Million INR | 3.61% |
2014 Q2 | 598.78 Million INR | 0.0% |
2014 FY | 587.94 Million INR | 1.95% |
2014 Q4 | 587.94 Million INR | 0.0% |
2014 Q3 | - INR | -100.0% |
2014 Q1 | - INR | -100.0% |
2013 FY | 576.68 Million INR | 5.56% |
2013 Q1 | - INR | -100.0% |
2013 Q3 | - INR | -100.0% |
2013 Q2 | 544.92 Million INR | 0.0% |
2013 Q4 | 576.68 Million INR | 0.0% |
2012 FY | 546.29 Million INR | -5.21% |
2012 Q4 | 546.29 Million INR | 0.0% |
2012 Q2 | 565.14 Million INR | 0.0% |
2011 Q4 | 576.3 Million INR | 0.0% |
2011 Q2 | - INR | 0.0% |
2011 FY | 576.3 Million INR | 31.56% |
2010 FY | 438.04 Million INR | 22.81% |
2009 FY | 356.69 Million INR | -16.29% |
2008 FY | 426.08 Million INR | -22.84% |
2007 FY | 552.2 Million INR | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Ajanta Pharma Limited | 10.71 Billion INR | 97.229% |
Amrutanjan Health Care Limited | 783.82 Million INR | 62.139% |
Sigachi Industries Limited | 2.53 Billion INR | 88.276% |
Bal Pharma Limited | 2.51 Billion INR | 88.183% |
Ind-Swift Laboratories Limited | 2.28 Billion INR | 87.038% |
Medico Remedies Limited | 438.24 Million INR | 32.284% |
Lasa Supergenerics Limited | 541.92 Million INR | 45.24% |
Venus Remedies Limited | 1.39 Billion INR | 78.693% |
Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | 92.377% |
Alpa Laboratories Limited | 307.12 Million INR | 3.374% |
Nectar Lifesciences Limited | 11.21 Billion INR | 97.355% |
Shilpa Medicare Limited | 12.93 Billion INR | 97.705% |
Aarti Drugs Limited | 11.5 Billion INR | 97.42% |
Lupin Limited | 96.23 Billion INR | 99.692% |
Aurobindo Pharma Limited | 152.2 Billion INR | 99.805% |
Zydus Lifesciences Limited | 71.79 Billion INR | 99.587% |
Windlas Biotech Limited | 1.76 Billion INR | 83.164% |
Suven Life Sciences Limited | 148.62 Million INR | -99.676% |
Eris Lifesciences Limited | 38.26 Billion INR | 99.225% |
Valiant Laboratories Limited | 1.05 Billion INR | 71.958% |
J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | 97.229% |
Solara Active Pharma Sciences Limited | 14.14 Billion INR | 97.902% |
Ipca Laboratories Limited | 33.74 Billion INR | 99.121% |
Bliss GVS Pharma Limited | 2.1 Billion INR | 85.928% |
Achyut Healthcare Limited | 2.01 Million INR | -14642.176% |
Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 99.838% |
Bajaj HealthCare Limited | 4.86 Billion INR | 93.903% |
RPG Life Sciences Limited | 1.38 Billion INR | 78.499% |
Mankind Pharma Limited | 23.87 Billion INR | 98.757% |
Laurus Labs Limited | 42.71 Billion INR | 99.305% |
Piramal Pharma Limited | 74 Billion INR | 99.599% |
Syncom Formulations (India) Limited | 1.16 Billion INR | 74.532% |
Torrent Pharmaceuticals Limited | 82.05 Billion INR | 99.638% |
Alembic Pharmaceuticals Limited | 16.27 Billion INR | 98.176% |
Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 99.544% |
Unichem Laboratories Limited | 8.06 Billion INR | 96.322% |
Sequent Scientific Limited | 8.27 Billion INR | 96.413% |
Novartis India Limited | 1.8 Billion INR | 83.523% |
Wanbury Limited | 3.15 Billion INR | 90.596% |
Suven Pharmaceuticals Limited | 2.03 Billion INR | 85.412% |
Wockhardt Limited | 39.87 Billion INR | 99.256% |
Themis Medicare Limited | 1.88 Billion INR | 84.278% |
Jubilant Pharmova Limited | 61.27 Billion INR | 99.516% |
Glenmark Life Sciences Limited | 5.18 Billion INR | 94.272% |
Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 99.723% |
Divi's Laboratories Limited | 18.99 Billion INR | 98.437% |
NATCO Pharma Limited | 10.53 Billion INR | 97.182% |
Gufic Biosciences Limited | 5.59 Billion INR | 94.701% |
IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | 95.311% |
Ind-Swift Limited | 13.45 Billion INR | 97.794% |
Procter & Gamble Health Limited | 2.56 Billion INR | 88.413% |
FDC Limited | 3.7 Billion INR | 91.999% |
Krebs Biochemicals & Industries Limited | 2.97 Billion INR | 90.021% |
Granules India Limited | 22.95 Billion INR | 98.707% |
Medicamen Biotech Limited | 940.36 Million INR | 68.442% |
Alkem Laboratories Limited | 48.6 Billion INR | 99.389% |
AstraZeneca Pharma India Limited | 3.66 Billion INR | 91.894% |
Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -2.757% |
Brooks Laboratories Limited | 248.6 Million INR | -19.372% |
Megasoft Limited | 1.85 Billion INR | 83.986% |
ZIM Laboratories Limited | 2.08 Billion INR | 85.738% |
Strides Pharma Science Limited | 37.68 Billion INR | 99.212% |
Neuland Laboratories Limited | 5.49 Billion INR | 94.603% |
Morepen Laboratories Limited | 4.45 Billion INR | 93.346% |
Hikal Limited | 12.99 Billion INR | 97.716% |
Indoco Remedies Limited | 10.34 Billion INR | 97.131% |
Aarti Pharmalabs Limited | 8.25 Billion INR | 96.403% |
Kilitch Drugs (India) Limited | 643.88 Million INR | 53.911% |
Mangalam Drugs & Organics Limited | 1.97 Billion INR | 84.984% |
Hester Biosciences Limited | 3.59 Billion INR | 91.745% |